A critical interpretive synthesis of anti-novel coronavirus drugs. (2nd June 2020)

• Record Type: Journal Article
• Authors: Xiaoli, Ren; Yang, Bing
• Is Part Of: Journal of prescribing practice. Volume 2:Number 6(2020)
• Page Start: 286
• Page End: 290
• Publication Date: 2020-06-02
• Subjects: COVID-19 -- interferon-α -- lopinavir/ritonavir -- ribavirin -- chloroquine phosphate -- arbidol -- sars-cov-2 -- severe acute respiratory syndrome; Drugs -- Prescribing -- Periodicals; Nurse practitioners -- Periodicals; 615.1
• DOI: 10.12968/jprp.2020.2.6.286
• Languages: English
• ISSNs: 2631-8385

Abstract

Abstract : Objective: To statistically analyse the development and research progress of clinical trials of novel coronavirus disease drugs, and to provide references for their clinical trials and treatment. Methods: The following keywords were searched for: 'COVID-19', 'Interferon-α', 'Lopinavir/Ritonavir', 'Ribavirin', 'Chloroquine Phosphate', 'Arbidol', 'SARS-CoV-2', 'Severe Acute Respiratory Syndrome'. The search was conducted on the Chinese Journal Full-text Database, Chinese Biomedical Literature Database, Cochrane library, PubMed, as well as the website of the China National Health Commission to extract and evaluate relevant data. Results: Most studies used western medicine or traditional Chinese medicine and antiviral treatment. The main antiviral drugs used were interferon-α, lopinavir/ritonavir, ribavirin, chloroquine phosphate and arbido. Conclusions: At present, there are no specific therapeutic drugs. The novel coronavirus can be effectively controlled by rational use of interferon-α, lopinavir/ritonavir, ribavirin, chloroquine phosphate and arbidol.